首页> 外文期刊>Oncology reports >miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN
【24h】

miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN

机译:miR-494通过靶向PTEN促进肝癌中的细胞增殖,迁移和侵袭,并提高索拉非尼耐药性

获取原文
获取原文并翻译 | 示例
       

摘要

MicroRNA-494 (miR-494) acts as an oncomiR and is involved in tumor development, progression and metastasis, and confers resistance to chemotherapeutic drugs by targeting a number of molecules in several human cancers. However, the function and underlying molecular mechanism of miR-494 in hepatocellular carcinoma (HCC) has not been totally elucidated. In the present study, we determined the role played by miR-494 in HCC tissues and HCC cell lines using quantitative RT-PCR (RT-qPCR). The results showed that, miR-494 was significantly upregulated in HCC tissues and HCC cell lines. Additionally, a high miR-494 expression positively correlated with tumor differentiation (P<0.01), TNM stage (P<0.01) and lymph node metastasis (P<0.01). Luciferase reporter assays confirmed that miR-494 binds to the 3'-untranslated region (3'-UTR) of the phosphatase and tensin homolog (PTEN) mRNA and represses its translation. Functional analyses indicated that the upregulation of miR-494 promoted cell viability, migration and invasion, decreased cell apoptosis and cell cycle arrest at G1 stage, and conferred sorafenib resistance to HCC cell lines. Underexpression of PTEN by siRNA significantly attenuated the inhibitory effects of anti-miR-494 on the proliferation, migration and invasion of liver cancer cells. Mechanistic investigations revealed that miR-494 suppressed the expression of PTEN but increased the expression of PI3K and p-Akt, which contribute to the promotion of proliferation, migration and invasion, and increased sorafenib resistance to HCC cell lines. These findings suggested that miR-494 is a potential candidate for HCC therapeutics.
机译:MicroRNA-494(miR-494)充当oncomiR,并参与肿瘤的发生,发展和转移,并通过靶向多种人类癌症中的多种分子来赋予对化学治疗药物的抗性。但是,miR-494在肝细胞癌(HCC)中的功能和潜在的分子机制尚未完全阐明。在本研究中,我们使用定量RT-PCR(RT-qPCR)确定了miR-494在HCC组织和HCC细胞系中发挥的作用。结果表明,miR-494在HCC组织和HCC细胞系中显着上调。此外,miR-494的高表达与肿瘤分化(P <0.01),TNM分期(P <0.01)和淋巴结转移(P <0.01)呈正相关。萤光素酶报告基因检测证实miR-494与磷酸酶和tensin同源物(PTEN)mRNA的3'-非翻译区(3'-UTR)结合并抑制其翻译。功能分析表明,miR-494的上调可促进细胞活力,迁移和侵袭,减少细胞凋亡和在G1期阻滞细胞周期,并赋予索拉非尼对HCC细胞系的抗性。 siRNA导致PTEN的表达不足显着减弱了抗miR-494对肝癌细胞增殖,迁移和侵袭的抑制作用。机理研究表明,miR-494抑制了PTEN的表达,但增加了PI3K和p-Akt的表达,这有助于促进增殖,迁移和侵袭,并提高了索拉非尼对HCC细胞系的抵抗力。这些发现表明,miR-494是肝癌治疗的潜在候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号